Trials / Withdrawn
WithdrawnNCT02099149
Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days
Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not. Use this comparison to establish antibody levels associated with reductions in risk of GBS disease in infants aged less than 90 days.
Conditions
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-03-28
- Last updated
- 2014-07-24
Locations
1 site across 1 country: South Africa
Source: ClinicalTrials.gov record NCT02099149. Inclusion in this directory is not an endorsement.